Michael Silao, MD
Internal Medicine · Los Angeles, CANPI 1497706147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$840
- Bayer$670
- Novo Nordisk$573
- Boehringer Ingelheim$460
- Pfizer$454
- GSK$431
- plus $4K from 33 others
What the payments were for
- Food & beverage$7,05599%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $840 |
| Bayer | 28 | $670 |
| Novo Nordisk | 28 | $573 |
| Boehringer Ingelheim | 17 | $460 |
| Pfizer | 18 | $454 |
| GSK | 19 | $431 |
| Lilly USA, LLC | 15 | $383 |
| AstraZeneca | 19 | $341 |
| Arbor Pharmaceuticals, Inc. | 22 | $341 |
| Amgen(2 entities) | 17 | $331 |
| Gilead | 9 | $259 |
| Merck | 11 | $232 |
| Inari Medical, Inc. | 1 | $214 |
| Avanir Pharmaceuticals, Inc. | 7 | $160 |
| Johnson & Johnson | 6 | $154 |
| Amarin Pharma, Inc. | 5 | $120 |
| Redhill Biopharma Inc. | 7 | $117 |
| Phathom Pharmaceuticals, Inc. | 5 | $107 |
| Novartis | 4 | $101 |
| Sunovion Pharmaceuticals Inc. | 5 | $87 |
| Exact Sciences | 3 | $85 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Paratek Pharmaceuticals, Inc. | 3 | $66 |
| Smith+Nephew | 1 | $65 |
| Hikma Pharmaceuticals USA | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Boston Scientific | 2 | $53 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Viiv Healthcare Company | 1 | $31 |
| Lundbeck LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| CMP Pharma, Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$214
- CT THROMBECTOMY SYSTEM KIT$214
- Ozempic$125
- Kerendia$118
- XIFAXAN$101
How this compares
$7,103 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 247 | $194,905 |
| EliquisApixaban | 235 | $123,307 |
| OzempicSemaglutide | 69 | $101,686 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $64,629 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $47,775 |
| FarxigaDapagliflozin Propanediol | 65 | $45,883 |
| EntrestoSacubitril/Valsartan | 69 | $42,373 |
| TrulicityDulaglutide | 26 | $36,384 |
| JanuviaSitagliptin Phosphate | 28 | $36,196 |
| RybelsusSemaglutide | 32 | $35,880 |
| MounjaroTirzepatide | 26 | $26,497 |
| XareltoRivaroxaban | 23 | $21,267 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $19,804 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $19,193 |
| VascepaIcosapent Ethyl | 26 | $13,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr | $460 | $233,903293 claims |
| Novo NordiskOzempic, Rybelsus | $573 | $137,566101 claims |
| PfizerEliquis | $454 | $123,307235 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $431 | $73,944104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $383 | $62,88252 claims |
| GileadBiktarvy | $259 | $47,77512 claims |
| AstraZenecaFarxiga | $341 | $45,88365 claims |
| NovartisEntresto | $101 | $42,37369 claims |
| MerckJanuvia | $232 | $36,19628 claims |
| Johnson & JohnsonXarelto | $154 | $21,26723 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $341 | $15,35233 claims |
| AbbVieCreon | $22 | $4,23512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.